Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

Dams, Ritchell Van; Jiang, Naomi; Fuller, Donald B.; Loblaw, Andrew; Jiang, Tommy; Katz, Alan J.; Collins, Sean P.; Aghdam, Nima; Suy, Simeng; Stephans, Kevin L.; Yuan, Ye; Nickols, Nicholas G.; Murthy, Vedang; Telkhade, Tejshri; Kupelian, Patrick A.; Steinberg, Michael L.; Romero, Tahmineh; Kishan, Amar U.

doi:10.1016/j.ijrobp.2021.01.016

Cited by 42 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rectum, bladder and urethra), which is a concern with SBRT or other radiation modalities. Furthermore, while prostate SBRT has demonstrated rates of cancer control similar to conventionally fractionated radiation, 5-20% of patients will develop biochemical failure following treatment 1,5,6 .…”

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance–Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort

Leeman

Cagney

Mak

et al. 2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance–Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort

Leeman

Cagney

Mak

et al. 2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…A prospective analysis of 344 SBRT-treated patients with a median follow-up of 4.1 years has recently been published, describing a bRFS rate of 81.7% and an MFS rate of 89.1% [34]. Katz et al [35] provide the longest follow-up data for this subgroup, with a median follow-up of eight years.…”

Section: Sbrt As Monotherapymentioning

confidence: 99%

“…The use of ADT was associated with an increase in bRFS in the multivariate analysis (p-value: 0.009), although without any difference in metastasis-free survival. [34].…”

Section: Sbrt and Androgen Deprivation Therapymentioning

confidence: 99%

“…At this time, we cannot establish the true role of ADT or its optimal duration in high-risk patients treated with SBRT, given the lack of sufficient levels of evidence for this subgroup of patients. Regarding the optimal sequencing to administer treatment with ADT in combination with SBRT in localized prostate cancer, there are no data in published studies in which ADT is used that indicate the optimal period to start ADT treatment [34,44], using as reference the timing established in studies employing normo-or moderate hypofractionated regimens [41][42][43].…”

Section: Sbrt and Androgen Deprivation Therapymentioning

confidence: 99%

See 1 more Smart Citation

Extreme Hypofractionation with SBRT in Localized Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological insights to shorten the overall treatment time, improving the control of the disease without increasing toxicities. Stereotactic body radiation therapy (SBRT) represents an extreme form of hypofractionated radiotherapy in which treatment is usually delivered in 1–5 fractions. This review assesses the main efficacy and toxicity data of SBRT in non-metastatic prostate cancer and discusses the potential to implement this scheme in routine clinical practice.

show abstract

“…The adoption of ultra-hypofractionated treatment regimens allows for decreased total treatment duration to one to two weeks. Recent studies comparing conventionally fractionated and ultra-fractionated radiation therapy have demonstrated the safety and efficacy of ultra-fractionation (6)(7)(8). As such, stereotactic body radiation therapy (SBRT) has been increasingly adopted in centers across the world.…”

Section: Introductionmentioning

confidence: 99%

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundDuring the course of radiation treatment for prostate cancer, patients may have unintentional interruptions in their treatment course due to a wide variety of factors. Stereotactic body radiation therapy (SBRT) decreases the number of treatments compared to conventionally fractionated radiation; hence, it has the potential to decrease treatment delays and non-completion. This study sought to determine the incidence of treatment delay and characterize the etiology and length in a large cohort of men treated with SBRT for their prostate cancer.MethodsOne thousand three hundred and thirty-six patients treated with SBRT from 2008 to 2021 at the Georgetown University Hospital for prostate cancer were included in this retrospective study. A treatment delay was defined as a patient requiring longer than 14 days to complete 5 fractions of SBRT. Non-completion was defined as patients treated with less than 5 fractions. In the patients who experienced delays, chart review was performed to characterize the length and etiology of each delay. Multivariate analysis was performed via binary logistic regression modeling on PSPP.ResultsAll individuals in the cohort eventually completed the planned 5-fraction regimen. Thirty-three patients experienced a treatment delay. Median length of time to complete treatment was 11 days (range 5–155 days). In patients who experienced a delay, nearly half (45.5%) experienced only a one-day delay. The most common reason for a delay was a technical issue (48.5%), including the machine maintenance, fiducial misalignment, or inadequate pretreatment bowel preparation. Other reasons included unplanned breaks due to acute side effects (21.2%), logistical issues (18.2%), non-treatment related health issues (9.1%), and inclement weather (3.0%). There were no significant sociodemographic, oncologic, or treatment variables that predicted treatment interruption on multivariate analysis.ConclusionsThe incidence of treatment interruptions in patients undergoing SBRT for their prostate cancer was low. Most treatment delays were short.

show abstract

Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

Cited by 42 publications

References 15 publications

Magnetic Resonance–Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort

Magnetic Resonance–Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort

Extreme Hypofractionation with SBRT in Localized Prostate Cancer

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

Contact Info

Product

Resources

About